Abstract
Purpose: :
To evaluate the effect of combined reduced-fluence photodynamic therapy and intravitreal anti-VEGF antibody injection for the treatment of myopic choroidal neovascularization.
Methods: :
13 eyes of 13 patients who underwent combined reduced-fluence photodynamic therapy and intravitreal anti-VEGF antibody injection for the myopic CNV, and were followed up more than 12 months. Their medical records were retrospectively investigated and the best corrected visual acuity, central macular thickness, and leak in fluorescein angiography were compared.
Results: :
The mean best corrected visual acuity(logMAR) was 1.03, 0.88, 0.76, 0.71, 0.73 at baseline, 1, 3, 6, 12 months(P<0.05). The mean central macular thickness was 292.46µm, 185.46µm at baseline, 3 months. In fluorescein angiography at 3 months after treatment, resolution was observed in 5 eyes, and reduction in 8 eyes.
Conclusions: :
Combined reduced-fluence photodynamic therapy and intravitreal anti-VEGF antibody injection for the myopic CNV appeared to be effective in regression of lesion and improvement of visual acuity.
Keywords: choroid: neovascularization • myopia • vascular endothelial growth factor